These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20559567)

  • 1. HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activity.
    Matoba N; Husk AS; Barnett BW; Pickel MM; Arntzen CJ; Montefiori DC; Takahashi A; Tanno K; Omura S; Cao H; Mooney JP; Hanson CV; Tanaka H
    PLoS One; 2010 Jun; 5(6):e11143. PubMed ID: 20559567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope.
    Hoorelbeke B; Huskens D; Férir G; François KO; Takahashi A; Van Laethem K; Schols D; Tanaka H; Balzarini J
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3287-301. PubMed ID: 20498311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The high mannose-type glycan binding lectin actinohivin: dimerization greatly improves anti-HIV activity.
    Takahashi A; Inokoshi J; Hachiya A; Oka S; Omura S; Tanaka H
    J Antibiot (Tokyo); 2011 Aug; 64(8):551-7. PubMed ID: 21694730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism by which the lectin actinohivin blocks HIV infection of target cells.
    Tanaka H; Chiba H; Inokoshi J; Kuno A; Sugai T; Takahashi A; Ito Y; Tsunoda M; Suzuki K; Takénaka A; Sekiguchi T; Umeyama H; Hirabayashi J; Omura S
    Proc Natl Acad Sci U S A; 2009 Sep; 106(37):15633-8. PubMed ID: 19717426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
    Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actinohivin, a novel anti-HIV protein from an actinomycete that inhibits syncytium formation: isolation, characterization, and biological activities.
    Chiba H; Inokoshi J; Okamoto M; Asanuma S; Matsuzaki Ki ; Iwama M; Mizumoto K; Tanaka H; Oheda M; Fujita K; Nakashima H; Shinose M; Takahashi Y; Omura S
    Biochem Biophys Res Commun; 2001 Mar; 282(2):595-601. PubMed ID: 11401502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Essential regions for antiviral activities of actinohivin, a sugar-binding anti-human immunodeficiency virus protein from an actinomycete.
    Takahashi A; Inokoshi J; Chiba H; Omura S; Tanaka H
    Arch Biochem Biophys; 2005 May; 437(2):233-40. PubMed ID: 15850563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
    Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The characteristic structure of anti-HIV actinohivin in complex with three HMTG D1 chains of HIV-gp120.
    Zhang F; Hoque MM; Jiang J; Suzuki K; Tsunoda M; Takeda Y; Ito Y; Kawai G; Tanaka H; Takénaka A
    Chembiochem; 2014 Dec; 15(18):2766-73. PubMed ID: 25403811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.
    Verrier F; Burda S; Belshe R; Duliege AM; Excler JL; Klein M; Zolla-Pazner S
    J Virol; 2000 Nov; 74(21):10025-33. PubMed ID: 11024131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile.
    Huskens D; Férir G; Vermeire K; Kehr JC; Balzarini J; Dittmann E; Schols D
    J Biol Chem; 2010 Aug; 285(32):24845-54. PubMed ID: 20507987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Actinohivin, a novel anti-human immunodeficiency virus protein from an actinomycete, inhibits viral entry to cells by binding high-mannose type sugar chains of gp120.
    Chiba H; Inokoshi J; Nakashima H; Omura S; Tanaka H
    Biochem Biophys Res Commun; 2004 Mar; 316(1):203-10. PubMed ID: 15003531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.
    Quiñones-Kochs MI; Buonocore L; Rose JK
    J Virol; 2002 May; 76(9):4199-211. PubMed ID: 11932385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.
    Zhang H; Fu H; Luallen RJ; Liu B; Lee FH; Doms RW; Geng Y
    Vaccine; 2015 Sep; 33(39):5140-7. PubMed ID: 26277072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.
    Gombos RB; Kolodkin-Gal D; Eslamizar L; Owuor JO; Mazzola E; Gonzalez AM; Korioth-Schmitz B; Gelman RS; Montefiori DC; Haynes BF; Schmitz JE
    J Virol; 2015 Aug; 89(15):7813-28. PubMed ID: 25995259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
    Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
    J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of the Envelope Glycoprotein of HIV-1 Clade B toward Higher Infectious Properties over the Course of the Epidemic.
    Bouvin-Pley M; Beretta M; Moreau A; Roch E; Essat A; Goujard C; Chaix ML; Moiré N; Martin L; Meyer L; Barin F; Braibant M
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses.
    Karlsson GB; Gao F; Robinson J; Hahn B; Sodroski J
    J Virol; 1996 Sep; 70(9):6136-42. PubMed ID: 8709238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.